illdrink2that - yes the reference to a potential new director was very interesting indeed! I agree - that the appointment of Prof Sue could be read that NTCell technology will prosper. It would be unusual to make such an appointment on the grounds of a failed trial. However LCT may also see the appointment as a strategic move because the trail was indeed a duffer, with the company needing a strong injection of credibility to support the other products in the pipeline. I sense that former is the case though. And yes a business savvy, strategic thinking Director with commercial expertise to move LCT in a prosperous direction, would be another well needed injection.
Ann: LCT board changes, page-8
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $13.90K | 1.986M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 3764983 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 41489 | 1 |
View Market Depth
| Last trade - 10.57am 15/11/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |